Annovis Bio (ANVS) Competitors $2.72 -0.13 (-4.56%) Closing price 07/11/2025 03:59 PM EasternExtended Trading$2.73 +0.01 (+0.37%) As of 07/11/2025 06:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANVS vs. ALXO, LFVN, ACRS, NVCT, NLTX, MOLN, TIL, BIOA, CGEN, and ALECShould you be buying Annovis Bio stock or one of its competitors? The main competitors of Annovis Bio include ALX Oncology (ALXO), Lifevantage (LFVN), Aclaris Therapeutics (ACRS), Nuvectis Pharma (NVCT), Neoleukin Therapeutics (NLTX), Molecular Partners (MOLN), Instil Bio (TIL), BioAge Labs (BIOA), Compugen (CGEN), and Alector (ALEC). These companies are all part of the "pharmaceutical products" industry. Annovis Bio vs. Its Competitors ALX Oncology Lifevantage Aclaris Therapeutics Nuvectis Pharma Neoleukin Therapeutics Molecular Partners Instil Bio BioAge Labs Compugen Alector Annovis Bio (NYSE:ANVS) and ALX Oncology (NASDAQ:ALXO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, risk, media sentiment and profitability. Is ANVS or ALXO more profitable? ALX Oncology's return on equity of -104.43% beat Annovis Bio's return on equity.Company Net Margins Return on Equity Return on Assets Annovis BioN/A -300.56% -193.50% ALX Oncology N/A -104.43%-77.74% Do analysts prefer ANVS or ALXO? Annovis Bio presently has a consensus target price of $18.00, suggesting a potential upside of 561.76%. ALX Oncology has a consensus target price of $3.30, suggesting a potential upside of 583.94%. Given ALX Oncology's higher probable upside, analysts clearly believe ALX Oncology is more favorable than Annovis Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Annovis Bio 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.00ALX Oncology 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.71 Which has higher valuation & earnings, ANVS or ALXO? Annovis Bio is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnnovis BioN/AN/A-$24.59M-$2.16-1.26ALX OncologyN/AN/A-$134.85M-$2.47-0.20 Do institutionals & insiders have more ownership in ANVS or ALXO? 15.8% of Annovis Bio shares are owned by institutional investors. Comparatively, 98.0% of ALX Oncology shares are owned by institutional investors. 20.8% of Annovis Bio shares are owned by insiders. Comparatively, 21.0% of ALX Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has more volatility & risk, ANVS or ALXO? Annovis Bio has a beta of 1.57, suggesting that its share price is 57% more volatile than the S&P 500. Comparatively, ALX Oncology has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500. Does the media refer more to ANVS or ALXO? In the previous week, ALX Oncology had 3 more articles in the media than Annovis Bio. MarketBeat recorded 3 mentions for ALX Oncology and 0 mentions for Annovis Bio. ALX Oncology's average media sentiment score of 0.29 beat Annovis Bio's score of 0.00 indicating that ALX Oncology is being referred to more favorably in the news media. Company Overall Sentiment Annovis Bio Neutral ALX Oncology Neutral SummaryALX Oncology beats Annovis Bio on 9 of the 14 factors compared between the two stocks. Get Annovis Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for ANVS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANVS vs. The Competition Export to ExcelMetricAnnovis BioMED IndustryMedical SectorNYSE ExchangeMarket Cap$55.54M$2.97B$5.62B$20.74BDividend YieldN/A2.39%5.24%3.71%P/E Ratio-1.2620.7128.1027.84Price / SalesN/A292.05429.7042.35Price / CashN/A42.8637.4622.63Price / Book4.067.638.044.57Net Income-$24.59M-$55.05M$3.18B$989.30M7 Day Performance14.05%8.43%3.61%0.20%1 Month Performance-7.80%5.42%4.04%3.95%1 Year Performance-77.78%2.03%29.99%10.27% Annovis Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANVSAnnovis Bio1.565 of 5 stars$2.72-4.6%$18.00+561.8%-79.4%$55.54MN/A-1.263ALXOALX Oncology3.5918 of 5 stars$0.42+2.3%$3.30+695.0%-93.7%$21.67MN/A0.0040News CoverageGap UpLFVNLifevantage4.3383 of 5 stars$13.08+3.1%$30.50+133.2%+99.8%$159.74M$200.16M18.96260Positive NewsACRSAclaris Therapeutics2.2344 of 5 stars$1.42-3.4%$9.71+584.1%+24.6%$159.17M$18.72M-1.02100Analyst ForecastGap UpNVCTNuvectis Pharma3.365 of 5 stars$7.47-1.1%$17.00+127.6%+23.1%$157.75MN/A0.008NLTXNeoleukin TherapeuticsN/A$16.16-2.5%N/A-49.1%$151.87MN/A-5.2090High Trading VolumeMOLNMolecular Partners3.1272 of 5 stars$3.79+0.8%$12.00+216.6%-47.1%$151.81M$5.65M0.00180TILInstil Bio3.3787 of 5 stars$20.83-9.3%$119.00+471.3%+152.5%$150.66MN/A-1.74410Positive NewsGap DownBIOABioAge LabsN/A$4.13-1.7%N/AN/A$150.57MN/A0.00N/ACGENCompugen1.7847 of 5 stars$1.78+7.2%$4.00+124.7%-9.1%$148.13M$27.86M-11.1370Gap UpALECAlector3.9984 of 5 stars$1.40-5.4%$4.00+185.7%-70.2%$147.99M$100.56M-1.11270News Coverage Related Companies and Tools Related Companies ALX Oncology Competitors Lifevantage Competitors Aclaris Therapeutics Competitors Nuvectis Pharma Competitors Neoleukin Therapeutics Competitors Molecular Partners Competitors Instil Bio Competitors BioAge Labs Competitors Compugen Competitors Alector Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ANVS) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Annovis Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Annovis Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ANVS Stock Alerts